Construction and Functional Analysis of Luciferase Reporter Plasmid Containing PCNA Gene Promoter

Abstract:

PCNA (proliferating cell nuclear antigen) is a protein related to tumor development, which has been used extensively in breast cancer diagnosis and prognosis. PCNA has proven to be a useful marker to evaluate cell proliferation and prognosis when combined with other breast cancer markers. Construction of PCNA promoter luciferase reporter plasmid will provide the theory basis for researching the effect of other transcription factors on regulating PCNA transcription. In this study, a human PCNA promoter luciferase reporter construct was generated by PCR amplification of PCNA promoter. The PCR fragment was digested and cloned into pGL3 vector. The promoter sequence was verified by sequencing. The results showed that luciferase reporter plasmids of PCNA promoter were successfully constructed. Then the effects of some key transcription factors, which play important roles in breast cancer cell proliferation, were investigated by luciferase reporter assays in MCF-7 cells. The results showed that ERα can enhance transcriptional activity of PCNA. Furthermore, 17-β-estradiol (E2) also shows an obvious impact in activating PCNA transcription. Our data illuminated that E2 enhances ERα-induced proliferation potential of MCF-7 cells by stimulating the transcriptional activity of PCNA. Our research will provide a model to screen some novel factors in regulating proliferation marker transcription.

• Periodical: Applied Mechanics and Materials (Volumes 556-562)
• Pages: 257-260
• DOI: https://doi.org/10.4028/www.scientific.net/AMM.556-562.257
• Online since: May 2014
• Authors: Tong Cun Zhang*, Yue Wang, Xing Hua Liao, Nan Wang, Hao Zhou
• Keywords: E2, Erα, Luciferase Activity Assay, MCF-7 Proliferation, PCNA

References

[1] Malkas LH, Herbert BS, Abdel-Aziz W, Dobrolecki LE, Liu Y, et al: Proc Nat Acad Sci USA, 103(51) (2006) p.19472–19477.

[2] Aaltomaa S, Lipponen P and Syrjänen K: Anticancer Res, 13(2) (1993) pp.533-8.

[3] Tahan SR, Neuberg DS, Dieffenbach A and Yacoub L: Cancer, 1; 71(11)(1993) pp.3552-9.

[4] De Santis C, Siegel R and Bandi P: Cancer Journal for Clinicians, 61(16) (2011) pp.408-418.

[5] Sanchez AM, Flamini MI, Baldacci C, et al: Mol Endocrinol , 24(11) (2010) pp.2114-2125.

[6] Clarke RB, Howell A, Potten CS, et al: Cancer Res, 57 (1997) pp.4987-4991.

[7] Petersen OW, Høyer PE and van Deurs B: Cancer Res, 47 (1987) pp.5748-5751.

[8] Sledge GW Jr and Miller KD: Eur J Cancer, 39(12) (2003) pp.1668-75.

[9] Lynch HT, Watson P, Tinley S, Snyder C, Durham C, Lynch J, Kirnarsky Y, Serova O, Lenoir G, Lerman C and Narod SA: Cancer Genet Cytogenet, 109(2) (1999) pp.91-8.

DOI: 10.1016/s0165-4608(98)00165-4

[10] Balfe P, McCann A, Welch H, et al: European Journal of Surgical Oncology, 30(10) (2004) pp.1043-1050.

[11] Ando-Lu J, Sasahara K, Nishiyama K, Takano S, Takahashi M, Yoshida M, Maekawa A: Exp Toxicol Pathol, 50(3) (1998) pp.185-90.

[12] Fuqua S, Schiff R, Parra I, et al: Cancer Research, 59(21) (1999) pp.5425-5428.

[13] Holst F, Stahl P, Ruiz C, et al: Nature Genetics, 39(5) (2007) pp.655-660.